VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

RBD-rAAV-SARS-CoV
Vaccine Information
  • Vaccine Name: RBD-rAAV-SARS-CoV
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Vaccine Ontology ID: VO_0004678
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Vector:
  • Preparation: Inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant (Zheng et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Intranasal vaccination with RBD-rAAV (Zheng et al., 2008).
  • Vaccine Immune Response Type: VO_0000287
  • Immune Response: Induced production of IgG and IgA that exhibited neutralizing activity. Induced a markedly higher level of antigen specific IL-2+ T cells but a slightly lower level of IFN-γ+ T cells in the spleen, IFN-γ-producing CD3+/CD8+ T cells were significantly higher in the splenocytes of RBD-rAAV intranasally versus intramuscularly vaccinated mice. (Zheng et al., 2008)
  • Challenge Protocol: Mice were challenged with 10^5 TCID50f SARS-CoV strain GZ50 (Zheng et al., 2008).
  • Efficacy: RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses (Zheng et al., 2008).
References
Zheng et al., 2008: Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Studies of SARS virus vaccines. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2008; 14 Suppl 4; 39-43. [PubMed: 18708674].